Inhibitors of cysteine proteases

Current Topics in Medicinal Chemistry

Volumn 6, Issue 4, 2006, Pages 331-353

  Vicik, Radim ^a   Busemann, Matthias ^a   Baumann, Knut ^a   Schirmeister, Tanja ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Aspergillus japonicus; AZIRIDINES; Caspases; Cruzain inhibitors; Epoxysuccinic acid; FUMARATES

Indexed keywords

ALOXISTATIN; AMINO ACID; AZIRIDINE 2,3 DICARBOXYLIC ACID; AZIRIDINE DERIVATIVE; CA 074; CALPAIN; CATHEPSIN B; CATHEPSIN F; CATHEPSIN H; CATHEPSIN K; CATHEPSIN L; CATHEPSIN S; CLICK 148; CRUZIPAIN; CYSTEINE; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL PEPTIDASE I; ETACRYNIC ACID; GLYCINE; LEUCINE; MIRAZIRIDINE A; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; NS 134; PAPAIN; PROTEINASE INHIBITOR; RUPINTRIVIR; SORTASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; BINDING SITE; COVALENT BOND; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; GENE TARGETING; HEART INFARCTION; IN VITRO STUDY; LIFE CYCLE; MULTIPLE SCLEROSIS; MUSCULAR DYSTROPHY; NONHUMAN; OSTEOPOROSIS; PROTEIN DEGRADATION; PROTEIN PROCESSING; PROTOZOON; REVIEW; STROKE; VIRUS STRAIN;

ANIMALS; AZIRIDINES; CARBOXYLIC ACIDS; CYSTEINE PROTEINASE INHIBITORS; EPOXY COMPOUNDS; FUMARATES; HUMANS; MODELS, MOLECULAR; SULFONES;

EID: 33646188959     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802606776287081     Document Type: Review

References (205)

1. Rawlings, N. D.; Barrett, A. J. MEROPS: the peptidase database. Nucleic Acids Res. 1999, 27, 325-31.
2. Barrett, A. J.; Rawlings, N. D.; O'Brien, E. A. The MEROPS database as a protease information system. J. Struct. Biol. 2001, 134, 95-102.
3. Rawlings, N. D.; Barrett, A. J. MEROPS: the peptidase database. Nucleic Acids Res. 2000, 28, 323-5.
4. Barrette, A. J. Bioinformatics of proteases in the MEROPS database. Curr. Opin. Drug. Discov. Devel. 2004, 7, 334-41.
5. Rawlings, N. D.; Tolle, D. P.; Barrett, A. J. Evolutionary families of peptidase inhibitors. Biochem. J. 2004, 378, 705-16.
6. Rawlings, N. D.; Tolle, D. P.; Barrett, A. J. MEROPS: the peptidase database. Nucleic Acids Res. 2004, 32, D160-4.
7. Rawlings, N. D.; O'Brien, E.; Barrett, A. J. MEROPS: the protease database. Nucleic Acids Res. 2002, 30, 343-6.
8. MEROPS (http://merops.sanger.ac.uk/).
9. Turk, B.; Turk, D.; Turk, V. Lysosomal cysteine proteases: more than scavengers. Biochim. Biophys. Acta 2000, 1477, 98-111.
10. Troen, B. R. The role of cathepsin K in normal bone resorption. Drug News Perspect. 2004, 17, 19-28.
11. Broker, L. E.; Huisman, C.; Span, S. W.; Rodriguez, J. A.; Kruyt, F. A.; Giaccone, G. Cathepsin B mediates caspase-independent cell death induced by microtubule stabilizing agents in non-small cell hung cancer cells. Cancer Res. 2004, 64, 27-30.
12. Szilagyi, L.; Kenesi, E,; Katona, G.; Kaslik, G.; Juhasz, G.; Graf, L. Comparative in vitro studies on native and recombinant human cationic trypsins. Cathepsin B is a possible pathological activator of trypsinogen in pancreatitis. J. Biol. Chem. 2001, 276, 24574-80.
13. Figarella, C.; Miszczuk-Jamska, B.; Barrett, A. J. Possible lysosomal activation of pancreatic zymogens. Activation of both human trypsinogens by cathepsin B and spontaneous acid. Activation of human trypsinogen 1. Biol. Chem. Hoppe-Seyler 1988, 369 Suppl, 293-8.
14. Goulet, B.; Baruch, A.; Moon, N. S.; Poirier, M.; Sansregret, L. L.; Erickson, A.; Bogyo, M.; Nepveu, A. A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor. Mol. Cell 2004, 14, 207-19.
15. Somoza, J. R.; Palmer, J. T.; Ho, J. D. The crystal structure of human cathepsin F and its implications for the development of novel immunomodulators. J. Mol. Biol. 2002, 322, 559-68.
16. Tolosa, E.; Li, W.; Yasuda, Y.; Wienhold, W.; Denzin, L. K.; Lautwein, A.; Driessen, C.; Schnorrer, P.; Weber, E.; Stevanovic, S.; Kurek, R.; Melms, A.; Bromme, D. Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis. J. Clin. Invest. 2003, 112, 517-26.
17. Leung-Toung, R.; Li, W.; Tam, T. F.; Karimian, K. Thioldependent enzymes and their inhibitors: a review. Curr. Med. Chem. 2002, 9, 979-1002.
18. Bromme, D.; Kaleta, J. Thiol-dependent cathepsins: pathophysiological implications and recent advances in inhibitor design. Curr. Pharm. Des. 2002, 8, 1639-58.
19. McGrath, M. E. The lysosomal cysteine proteases. Annu. Rev. Biophys. Biomol. Struct. 1999, 28,181-204.
20. Turk, D.; Gumcar, G. Lysosomal cysteine proteases (cathepsins): promising drug targets. Acta Crystallogr. 2003, 59, 203-213.
21. Lecaille, F.; Kaleta, J.; Bromine, D. Hunan and parasitic papainlike cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. Chem. Rev. 2002, 102, 4459-88.
22. Huang, Y.; Wang, K. K. The calpain family and human disease. Trends Mol. Med. 2001, 7, 355-62.
23. Talanian, R. V.; Brady, K. D.; Cryns, V. L. Caspases as targets for anti-inflammatory and anti-apoptotic drug discovery. J. Med. Chem. 2000, 43, 3351-71.
24. Wang, K. K. W.; Yuen, P. W. Calpain inhibition - an overview of its therapeutic potential. Trends Pharmacol. 1994, 15, 412-419.
25. Wang, K. K. Calpain and caspase: can you tell the difference? Trends Neurosci. 2000, 23, 20-6.
26. Earnshaw, W. C.; Martins, L. M.; Kaufmann, S. H. Mammalian caspases: Structure, activation, substrates, and functions during apoptosis. Annu. Rev. Biochem. 1999, 68, 383-424.
27. Tong, L. Viral proteases. Chem. Rev. 2002, 102, 4609-26.
28. Bianchi, E.; Pessi, A. Inhibiting viral proteases: challenges and opportunities. Biopolymers 2002, 66, 101-14.
29. Gelb, B. D.; Shi, G. P.; Chapman, H. A.; Desnick, R. J. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996, 273, 1236-8.
30. Hou, W. S.; Broemme, D.; Zhao, Y.; Mehler, E.; Dushey, C.; Weinstein, H.; Miranda, C. S.; Fraga, C.; Greig, F.; Carey, J.; Rimoin, D. L.; Desnick, R. J.; Gelb, B. D. Characterization of novel cathepsin K mutations in the pro and mature polypeptide regions causing pycnodysostosis. J. Clin. Invest. 1999, 103, 731-8.
31. Dodds, R. A.; Connor, J. R.; Drake, F. H.; Gowen, M. Expression of cathepsin K messenger RNA in giant cells and their precursors in human osteoarthritic synovial tissues. Arthritis. Rheum. 1999, 42, 1588-93.
32. Drake, F. H.; Dodds, R. A.; James, I. E.; Connor, J. R.; Debouck, C.; Richardson, S.; Lee-Rykaczewski, E.; Coleman, L.; Rieman, D.; Barthlow, R.; Hastings, G.; Gowen, M. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J. Biol. Chem. 1996, 271, 12511-6.
33. Hummel, K. M.; Petrow, P. K.; Franz, J. K.; Muller-Ladner, U.; Aicher, W. K.; Gay, R. E.; Bromine, D.; Gay, S. Cysteine proteinase cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction. J. Rheumatol, 1998, 25, 1887-94.
34. Isomaki, P.; Punnonen, J. Pro- and anti-inflammatory cytokines in rheumatoid arthritis. Ann. Med. 1997, 29, 499-507.
35. Vincenti, M. P.; Coon, C. I.; Brinckerhoff, C. E. Nuclear factor kappaB/ p50 activates an element in the distal matrix metalloproteinase 1 promoter in interleukin-1beta-stimulated synovial fibroblasts. Arthritis. Rheum. 1998, 41, 1987-94.
36. Goretzki, L.; Schmitt, M.; Mann, K.; Calvete, J.; Chucholowski, N.; Kramer, M.; Gunzler, W. A.; Janicke, F.; Graeff, H. Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L. FEBS Lett. 1992, 297, 112-8.
37. Bervar, A.; Zajc, I.; Sever, N.; Katunuma, N.; Sloane, B. F.; Lah, T. T. Invasiveness of transformed human breast epithelial cell lines is related to cathepsin B and inhibited by cysteine proteinase inhibitors. Biol. Chem. 2003, 384, 447-55.
38. Werle, B.; Kraft, C.; Lah, T. T.; Kos, J.; Schanzenbacher, U.; Kayser, K.; Ebert, W.; Spiess, E. Cathepsin B in infiltrated lymph nodes is of prognostic significance for patients with nonsmall cell lung carcinoma. Cancer 2000, 89, 2282-91.
39. Kos, J.; Werle, B.; Lah, T.; Brunner, N. Cysteine proteinases and their inhibitors in extracellular fluids: markers for diagnosis and prognosis in cancer. Int. J. Biol. Markers 2000, 15, 84-9.
40. Shi, G. P.; Sukhova, G. K.; Kuzuya, M.; Ye, Q.; Du, J.; Zhang, Y.; Pan, J. H.; Lu, M. L.; Cheng, X. W.; Iguchi, A.; Perrey, S.; Lee, A. M.; Chapman, H. A.; Libby, P. Deficiency of the cysteine protease cathepsin S impairs microvessel growth. Circ. Res. 2003, 92, 493-500.
41. Sukhova, G. K.; Zhang, Y.; Pan, J. H.; Wada, Y.; Yamamoto, T.; Naito, M.; Kodama, T.; Tsimikas, S.; Witztum, J. L.; Lu, M. L.; Sakara, Y.; Chin, M. T.; Libby, P.; Shi, G. P. Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 2003, 111, 897-906.
42. Driessen, C.; Bryant, R. A.; Lennon-Dumenil, A. M.; Villadangos, J. A.; Bryant, P. W.; Shi, G. P.; Chapman, H. A.; Ploegh, H. L. Cathepsin S controls the trafficking and maturation of MHC class II molecules in dendritic cells. J. Cell Biol. 1999, 147, 775-90.
43. Villadangos, J. A.; Bryant, R. A.; Deussing, J.; Driessen, C.; Lennon-Dumenil, A. M.; Riese, R. J.; Roth, W.; Saffig, P.; Shi, G. P.; Chapman, H. A.; Peters, C.; Ploegh, H. L. Proteases involved in MHC class II antigen presentation. Immunol. Rev. 1999, 172, 109-20.
44. Goll, D. E.; Thompson, V. F.; Li, H.; Wei, W.; Cong, J. The calpain system. Physiol. Rev. 2003, 83, 731-801.
45. Thornberry, N. A.; Lazebnik, Y. Caspases: Enemies within. Science 1998 281, 1312-1316.
46. Fuentes-Prior, P.; Salvesen, G. S. The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem. J. 2004, 384, 201-32.
47. Pink, R.; Hudson, A.; Mouries, M. A.; Bendig, M. Opportunities and challenges in antiparasitic drug discovery. Nat. Rev. Drug Discov. 2005, 4, 727-40.
48. McKerrow, J. H. Parasite proteases. Exp. Parasitol. 1989, 68, 111 -5.
49. Rosenthal, P. J. Proteases of protozoan parasites. Adv. Parasitol. 1999, 43, 105-59.
50. Tort, J.; Brindley, P. J.; Knox, D.; Wolfe, K. H.; Dalton, J. P. Proteinases and associated genes of parasitic helminths. Adv. Parasitol. 1999, 43, 161-266.
51. Rosenthal, P. J.; Sijwuli, P. S.; Singh, A.; Shenai, B. R. Cysteine proteases of malaria parasites: targets for chemotherapy. Curr. Pharm. Des. 2002, 8, 1659-72.
52. Eakin, A. E.; McGrath, M. E.; McKerrow, J. H.; Fletterick, R. J.; Craik, C. S. Production of crystallizable cruzain, the major cysteine protease from Trypanosoma cruzi. J. Biol. Chem. 1993, 268, 6115-8.
53. Caffrey, C. R.; Hartsell, E.; Lucas, K. D.; Brinen, L. S.; Alvarez Hernandez, A.; Cheng, J.; Gwaltney, S. L., 2nd, Roush, W. R.; Stierhof, Y. D.; Bogyo, M.; Steverding, D.; McKerrow, J. H. Active site mapping, biochemical properties and subcellular localization of rhodesain, the major cysteine protease of Trypanosoma brucei rhodesiense. Mol. Biochem. Parasitol. 2001, 118, 61-73.
54. Mottram, J. C.; Brooks, D. R.; Coombs, G. H. Roles of cysteine proteinases of trypanosomes and Leishmania in host-parasite interactions. Curr. Opin-Vicroblol. 1998, 1, 455-60.
55. Kim, J. C.; Spence, R. A.; Currier, P. F.; Lu, X. T.; Denison, M. R. Coronavirus protein processing and RNA-synthesis is inhibited by the cysteine proteinase-inhibitor E64d. Virology 1995, 208, 1-8.
56. Hernandez, A. A.; Roush, W. R. Recent advances in the synthesis, design and selection of cysteine protease inhibitors. Curr. Opin. Chem. Biol. 2002, 6, 459-65.
57. Powers, J. C.; Asgian, J. L.; Ekici, O. D.; James, K. E. Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem. Rev. 2002, 102, 4639-750.
58. Knight, C. G., The characterization of enzyme inhibition. Elsevier: Amsterdam, 1986; pp. 23-51.
59. Otto, H. H.; Schirmeister, T. Cysteine Proteases and Their Inhibitors. Chem. Rev. 1997, 97, 133-172.
60. Schirmeister, T.; Klockow, A. Cysteine protease inhibitors containing small rings. Mini Rev. Med. Chem. 2003, 3, 585-96.
61. Hanada, K.; Tamai, M.; Yamagishi, M.; Ohmura, S.; Sawada, J.; Tanaka, I. Isolation and characterization of E-64, a new thiol protease inhibitor. Agric. Biol. Chem. 1978, 42, 523-528.
62. Bajusz, S.; Fauszt, I.; Nemeth, K.; Barabas, E.; Juhasz, A.; Patthy, M.; Bauer, P. I. Peptidyl beta-homo-aspartals (3-amino4-carboxybutyraldehydes): new specific inhibitors of caspases. Blopolymers 1999, 51, 109-18.
63. Ho, J. D.; Meltser, Y.; Buggy, J. J.; Palmer, J. T.; Elrod, K. C.; Chan, H.; Mortara, K. D.; Somoza, J. R. Expression, purification, crystallization and preliminary X-ray diffraction studies of human cathepsin F complexed with an irreversible vinyl sulfone inhibitor. Acta Crystallogr. D Biol. Crystallogr. 2002, 58, 2187-90.
64. Yamamoto, A.; Tomoo, K.; Matsugi, K.; Hara, T.; In, Y.; Murata, M.; Kitamura, K.; Ishida, T. Structural basis for development of cathepsin B-specific noncovalent-type inhibitor: crystal structure of cathepsin B-E64c complex. Biochim. Biophys. Acta 2002, 1597, 244-51.
65. Yamamoto, A.; Tomoo, K.; Hara, T.; Murata, M.; Kitamura, K.; Ishida, T. Substrate specificity of bovine cathepsin B and its inhibition by CA074, based on crystal structure refinement of the complex. J. Biochem. (Tokyo) 2000, 127, 635-43.
66. Tsuge, H.; Nishimura, T.; Tada, Y.; Asao, T.; Turk, D.; Turk, V.; Katunuma, N. Inhibition mechanism of cathepsin L-specific inhibitors based on the crystal structure of papain-CLIK148 complex. Biochem. Biophys. Res. Co. 1999, 266, 411-6.
67. Marquis, R. W.; Ru, Y.; Yamashita, D. S.; Oh, H. J.; Yen, J.; Thompson, S. K.; Carr, T. J.; Levy, M. A.; Tomaszek, T. A.; Ijames, C. F.; Smith, W. W.; Zhao, B.; Janson, C. A.; Abdel-Meguid, S. S.; D'Alessio, K. J.; McQueney, M. S.; Veber, D. F. Potent dipeptidylketone inhibitors of the cysteine protease cathepsin K. Bioorg. Med. Chem. 1999, 7. 581-8.
68. Matsumoto, K.; Murata, M.; Sumiya, S.; Mizoue, K.; Kitamura, K.; Ishida, T. X-ray crystal structure of papain complexed. with cathepsin B-specific covalent-type inhibitor: substrate specificity and inhibitory activity. Biochim. Biophys. Acta 1998, 1383, 93-100.
69. Yamamoto, A.; Hara, T.; Tomoo, K.; Ishida, T.; Fujii, T.; Hata, Y.; Murata, M.; Kitamura, K. Binding mode of CA074, a specific irreversible inhibitor, to bovine cadiepsin B as determined by X-ray crystal analysis of the complex. J. Biochem. (Tokyo) 1997, 121, 974-7.
70. Fujishima, A.; Imai, Y.; Nomura, T.; Fujisawa, Y.; Yamamoto, Y.; Sugawara, T. The crystal structure of human cathepsin L complexed with E-64. FEBS Lett. 1997, 407, 47-50.
71. Jia, Z.; Hasnain, S.; Hirama, T.; Lee, X.; Mort, J. S.; To, R.; Huber, C. P. Crystal structures of recombinant rat cathepsin B and a cathelisin B-inhibitor complex. Implications for structure-based inhibitor design. J. Biol. Chem. 1995, 270, 5527-33.
72. Kim, M. J.; Yamamoto, D.; Matsumoto, K.; Inoue, M.; Ishida, T.; Mizuno, H.; Sumiya, S.; Kitamura, K. Crystal structure of papain-E64-c complex. Binding diversity of E64-c to papain S2 and S3 subsites. Biochem. J. 1992, 287 (Pt 3), 797-803.
73. Yamamoto, D.; Matsumoto, K.; Ohishi, H.; Ishida, T.; Inoue, M.; Kitamura, K.; Mizuno, H. Refined x-ray structure of papain.E-64-c complex at 2.1-A resolution. J. Biol. Chem. 1991, 266, 14771-7.
74. Greenbaum, D. C.; Arnold, W. D.; Lu, F.; Hayrapetian, L.; Baruch, A.; Krumrine, J.; Toba, S.; Chehade, K.; Bromine, D.; Kuntz, I. D.; Bogyo, M. Small molecule affinity fingerprinting. A tool for enzyme family subclassification, target identification, and inhibitor design. Chem. Biol. 2002, 9, 1085-94.
75. Gour-Salin, B. J.; Lachance, P.; Magny, M. C.; Plouffe, C.; Menard, R.; Storer, A. C. E64 [tram-epoxysuccinyl-L-leucylamido-(4-guanidino)butane) analogues as inhibitors of cysteine proteinases: investigation of S2 subsite interactions. Biochem. J. 1994, 299 (Pt 2), 389-92.
76. McGowan, E. B.; Becker, E.; Detwiler, T. C. Inhibition of calpain in intact platelets by the thiol protease inhibitor E-64d. Biochem. Biophys. Res. Commun. 1989, 158, 432-5.
77. Murray, E. J.; Grisanti, M. S.; Bentley, G. V.; Murray, S. S. E64d, a membrane-permeable cysteine protease inhibitor, attenuates the effects of parathyroid hormone on osteoblasts in vitro. Metabolism 1997, 46, 10904.
78. N.N. EST. Drugs Fut. 1986, 11, 927-930.
79. N.N. Scrip 1992, 1765, 11.
80. Towatari, T.; Nikawa, T.; Murata, M.; Yokoo, C.; Tamai, M.; Hanada, Y.; Katunuma, N. Novel epoxysuccinyl peptides. A selective inhibitor of cathepsin B, in vivo. FEBS Lett. 1991, 280, 311-5.
81. Murata, M.; Miyashita, S.; Yokoo, C.; Tamai, M.; Hanada, K.; Hatayama, K.; Towatari, T.; Nikawa, T.; Katinuma, N. Novel epoxysuccinyl peptides. Selective inhibitors of cathepsin B, in vitro. FEBS Lett. 1991, 280, 307-10.
82. Bogyo, M.; Verhelst, S.; Bellingard-Dubouchaud, V.; Toba, S.; Greenbaum, D. Selective targeting of lysosomal cysteine proteases with radiolabeled electrophilic substrate analogs. Chem. Biol. 2000, 7, 27-38.
83. Schaschke, N.; AssfalgMachleidt, I.; Machleidt, W.; Turk, D.; Moroder, L. E-64 analogues as inhibitors of cathepsin B. On the role of the absolute configuration of the epoxysuccinyl group. Bioorg. Med. Chem. 1997, 5, 1789-1797.
84. Katunuma, N.; Murata, E.; Kakegawa, H.; Matsui, A.; Tsuzuki, H.; Tsuge, H.; Turk, D.; Turk, V.; Fukushima, M.; Tada, Y.; Asao, T. Structure based development of novel specific inhibitors for cathepsin L and cathepsin S in vitro and in vivo. FEBS Lett. 1999, 458, 6-10.
85. Roush, W. R.; Gonzalez, F. V.; McKerrow, J. H.; Hansell, E. Design and synthesis of dipeptidyl alpha',beta'-epoxy ketones, potent irreversible inhibitors of the cysteine protease cruzain. Bioorg. Med. Chem. Lett. 1998, 8, 2809-12.
86. James, K. E.; Asgian, J. L.; Li, Z. Z.; Ekici, O. D.; Rubin, J. R.; Mikolajczyk, J.; Salvesen, G. S.; Powers, J. C. Design, synthesis, and evaluation of aza-peptide epoxides as selective and potent inhibitors of caspases-1, -3, -6, and -8. J. Med, Chem. 2004, 47, 1553-74.
87. Caldera, P. S.; Yu, Z.; Knegtel, R. M.; McPhee, F.; Burlingame, A. L.; Craik, C. S.; Kuntz, I. D.; Ortiz de Montellano, P. R. Alkylation of a catalytic aspartate group of the SIV protease by an epoxide inhibitor. Bioorg. Med. Chem. 1997, 5, 2019-27.
88. Rose, R. B.; Rose, J. R.; Salto, R.; Craik, C. S.; Stroud, R. M. Structure of the protease from simian immunodeficiency virus: complex with an irreversible nonpeptide inhibitor. Biochemistry 1993, 32, 12498-507.
89. Ro, S.; Baek, S. G.; Lee, B.; Ok, J. H. Conformational studies of irreversible HIV-1 protease inhibitors containing cis-epoxide as an amide isostere. J Pept. Res. 1999, 54, 242-8.
90. James, K. E.; Gotz, M. G.; Caffrey, C. R.; Hansell, E.; Carter, W.; Barrett, A. J.; McKerrow, J. H.; Powers, J. C. Aza-peptide epoxides: potent and selective inhibitors of Schistosoma mansoni and pig kidney legumains (asparaginyl endopeptidases). Biol. Chem. 2003, 384, 1613-8.
91. Asgian, J. L.; James, K. E.; Li, Z. Z.; Carter, W.; Barrett A. J.; Mikolajczyk, J.; Salvesen, G. S.; Powers, J. C. Aza-peptide epoxides: a new class of inhibitors selective for clan CD cysteine proteases. J. Med. Chem. 2002, 45, 4958-60.
92. Martichonok, V.; Plouffe, C.; Storer, A. C.; Menard, R.; Jones, J. B. Aziridine Analogs of Trans-(Epoxysuccinyl)-L-Leucyl] Amino]4-Guanidinob utane (E-64) as Inhibitors of Cysteine Proteases. J Med. Chem. 1995, 38, 3078-3085.
93. a Moroder, L.; Musiol, H. J.; Scharf, R. Aziridine-2-carboxylic acid. A reactive amino acid unit for a new class of cysteine proteinase inhibitors. FEBS Lett. 1992, 299, 51-3;
94. Korn, A.; Rudolph-Böhner, S.; Moroder, L. On the Synthesis of (2S)-Aziridine-2-Carboxylic Acid Containing Peptides. Tetrahedron 1994, 50, 1717-1730.
95. Schirmeister, T. Tziridine-2,3-dicarboxylic acid derivatives as inhibitors of papain.Arch. Pharm. 1996, 329, 239-244.
96. Woo, J. T.; Ono, H.; Tsuji, T. Cathestatins, new cysteine protease inhibitors produced by Penicillium citrinum. Biosci. Biotechnol. Biochem. 1995, 59, 350-2.
97. Otsuka, T.; Muramatsu, Y.; Niikura, K.; Okamoto, M.; Hino, M.; Hashimoto, S. WF14861, a new cathepsins B and L inhibitor produced by Colletotrichum sp. II. Biological properties. J Antibiot. (Tokyo) 1999, 52, 542-7.
98. Otsuka, T.; Muramatsu, Y.; Higaki, T.; Nakanishi, T.; Takase, S.; Hatanaka, H.; Okamoto, M.; Hino, M.; Hashimoto, S. WF14861, a new cathepsins B and L inhibitor produced by Colletotrichum sp. I. Taxonomy, production, purification and structure elucidation. J. Antibiot. (Tokyo) 1999, 52, 536-41.
99. Otsuka, T.; Muramatsu, Y.; Nakanishi, T.; Hatanaka, H.; Okamoto, M.; Hino, M.; Hashimoto, S. WF14865A and B, new cathepsins B and L inhibitors produced by Aphanoascus fulvescens. I. Taxonomy, production, purification and biological properties. J. Antibiot. (Tokyo) 2000, 53, 449-58.
100. Legters, J.; Thijs, L.; Zwanenburg, B. Synthesis of naturally-occurring (2S,3S)-(+)-aziridine-2,3-dicarboxylic Acid. Tetrahedron 1991, 47, 5287-5294.
101. Naganawa, H.; Usui, N.; Takita, T.; Hamada, M.; Umezawa, H. (S)-2,3-dicarboxy-aziridine, a new metabolite from a Streptomyces. J. Antibiot. (Tokyo) 1975, 28, 828-9.
102. Schaschke, N. Miraziridine A: natures blueprint towards protease class-spanning inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 855-857.
103. Nakao, Y.; Fujita, M.; Warabi, K.; Matsunaga, S.; Fusetani, N. Bioactive marine metabolites. Part 104. Miraziridine A, a novel cysteine protease inhibitor from the marine sponge Theonella aff. mirabilis. J. Am. Chem. Soc. 2000, 122, 10462-10463.
104. Castillo, I.; Lodeiros, C.; Nunez, M.; Campos, I. In vitro evaluation of antibacterial substances produced by bacteria isolated from different marine organisms. Rev. Biol. Trop. 2001, 49, 1213-22.
105. Lee, H. S.; Shin, H. J.; Jang, K. H.; Kim, T. S.; Oh, K. B.; Shin, J. Cyclic peptides of the nocardamine class from a marine-derived bacterium of the genus Streptomyces. J. Nat. Prod. 2005, 68, 623-5.
106. March, J., Advanced organic chemistry. 4th Ed. ed.; Wiley Interscience: 1992.
107. Eicher, T.; Hauptmann, S., The chemistry of heterocycles. Thieme Verlag: Stuttgart, New York, 1995.
108. Bihovsky, R.; Powers, J. C.; Kam, C. M.; Walton, R.; Loewi, R. C. Further evidence for the importance of free carboxylate in epoxysuccinate inhibitors of thiol proteases. J. Enzyme Inhib. 1993, 7, 15-25.
109. Meara, J. P.; Rich, D. H. Mechanistic studies on the inactivation of papain by epoxysuccinyl inhibitors. J. Med. Chem. 1996, 39, 3357-66
110. Bihovsky, R. Reactions of α,β-epoxy carbonyl-compounds with methanethiolate - regioselectivity and rate. J. Org. Chem. 1992, 57, 1029-1031.
111. Bihovsky, R.; Loewi, R. Reactivities of epoxides toward thiols - applications to papain inhibitors. Abst. Pap. ACS 1991, 202, 71-Medi.
112. Helten, H.; Schirmeister, T.; Engels, B. Model calculations about the influence of protic environments on the alkylation step of epoxíde, aziridine and thiirane based cysteine protease inhibitors. J. Phys. Chem. A 2004, 108, 7691-7701.
113. Helten, H.; Schirmeister, T.; Engels, B. Theoretical studies about the influence of different ring substituents on the nucleophilic ring opening of three-membered heterocycles and possible implications for the mechanisms of cysteine protease inhibitors. J. Org. Chem. 2005, 70, 233-237.
114. Schirmeister, T.; Peric, M. Aziridinyl peptides as inhibitors of cysteine proteases: effect of a free carboxylic acid function on inhibition. Bioorg. Med. Chem. 2000, 8, 1281-91.
115. Schirmeister, T. Inhibition of cysteine proteases by peptides containing aziridine-2,3-dicarboxylic acid building blocks. Biopolymers 1999, 51, 87-97.
116. Schirmeister, T. New peptidic cysteine protease inhibitors derived from the electrophilic alpha-amino acid aziridine-2,3-dicarboxylic acid. J. Med. Chem. 1999, 42, 560-72.
117. Schirmeister, T. Synthesis of peptides with aziridine-2,3-dicarboxylic acid as an alpha-amino acid equivalent building block. Pep. Sci. - Present and Future 1998, 654-656.
118. Vicik, R.; Busemann, M.; Gelhaus, C.; Stiefl, N.; Scheiber, J.; Schmitz, W.; Schulz, F.; Mladenovic, M.; Engels, B.; Leippe, M.; Baumann, K.; Schirmeister, T. Selective cathepsin L inhibitors targeting both primed and non-primed substrate binding sites. J. Med. Chem. 2005, in revision.
119. Vicik, R.; Hoerr, V.; Glaser, M.; Schultheis, M.; Hansell, E.; McKerrow, J. H.; Holzgrabe, U.; Caffrey, C. C.; Ponte-Sucre, A.; Moll, H.; Stich, A.; Schirmeister, T. Aziridine-2,3-dicarboxylate inhibitors targeting the major cysteine protease of Trypanosoma brucei as lead trypanocidal agents. Bioorg. Med. Chem. Lett. 2005, submitted.
120. a Ponte-Sucre, A.; Vicik, R; Schultheis, M.; Schirmeister, T.; Moll, H. Aziridine-2,3-dicarboxylates: Peptidomimetic cysteine protease inhibitors with antileishmanial activity.Antimicrob. Agents Chemother. 2005, submitted; b Vicik, R.; Jenke, F.; Schirmeister, T.; Gelhaus, C.; Leippe, M. unpublished results.
121. Martina, E.; Stiefl, N.; Degel, B.; Schulz, F.; Breuning, A.; Schiller, M.; Vick R.; Baumann, K.; Ziebuhr, K.; Schirmeister, T. Screening of electrophilic compounds yields an aziridinyl peptide as new active-site directed SARS-CoV main protease inhibitor. Bioorg. Med. Chem. Lett. 2005, 15, 5365-9.
122. Kramer, B.; Metz, G.; Rarey, M.; Lengauer, T. Ligand docking and screening with FlexX. Med. Chem. Res. 1999, 9, 463-478.
123. Kramer, B.; Rarey, M.; Lengauer, T. Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking. Proteins 1999, 37, 228-241.
124. Lemmen, C.; Hindle, S. A.; Gastreich, M.; Dramburg, I; Claussen, H. FlexX-docking: Past, present and planned technological advancements. Abst. Pap. ACS 2004, 228, U507-U507.
125. Schellhammer, I.; Rarey, M. FlexX-Scan: Fast, structure-based virtual screening. Proteins 2004, 57, 504-517.
126. Shao, H.; Jiang, X.; Gantzel, P.; Goodman, M. Tilted amides in amino acid and peptide derivatives. Chem. Biol. 1994, 1, 231-4
127. Gelhaus, C.; Vicik, R.; Hilgenfeld, R.; Schmidt, C. L.; Leippe, M.; Schirmeister, T. Synthesis and antiplasmodial activity of a cysteine protease-inhibiting biotinylated aziridine-2,3-dicarboxylate. Biol. Chem. 2004, 385, 435-438.
128. Gelhaus, C.; Vicik, R.; Schirmeister, T.; Leippe, M. Blocking effect of a biotinylated protease inhibitor on the egress of Plasmodium falciparum merozoites from infected red blood cells. Biol. Chem. 2005, 386, 499-502.
129. Greenbaum, D.; Medzihradszky, K. F.; Burlingame, A.; Bogyo, M. Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools. Chem. Biol 2000, 7, 569-81.
130. Schirmeister, T.; Breuning, A.; Murso, A.; Stalke, D.; Mladenovic, M.; Engels, B.; Szeghalmi, A.; Schmitt, M.; Kiefer, W.; Popp, J. Conformation and hydrogen bonding properties of an aziridinyl peptide: X-ray structure analysis, Raman spectroscopy and theoretical investigations. J. Phys. Chem. A 2004, 108, 11398-11408.
131. Barrett, A. J.; Kembhavi, A. A.; Brown, M. A.; Kirschke, H.; Knight, C. G.; Tamai, M.; Hanada, K. L-trans-Epoxysuccinyl-leucylamido (4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem. J. 1982, 201, 189-98.
132. Broemme, D.; Klaus, J. L.; Okamoto, K.; Rasnick, D.; Palmer, J. T. Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors: S2P2 specificity of human cathepsin O2 in comparison with cathepsins S and L. Biochem. J. 1996, 315 (Pt 1), 85-9.
133. Palmer, J. T.; Rasnick, D.; Klaus, J. L.; Bromme, D. Vinyl sulfones as mechanism-based cysteine protease inhibitors. J. Med. Chem. 1995, 38, 3193-6.
134. Matthews, D. A.; Dragovich, P. S.; Webber, S. E.; Fuhrman, S. A.; Patick, A. K.; Zalman, L. S.; Hendrickson, T. F.; Love, R. A.; Prins, T. J.; Marakovits, J. T.; Zhou, R.; Tikhe, J.; Ford, C. E.; Meador, J. W.; Ferre, R. A.; Brown, E. L.; Binford, S. L.; Brothers, M. A.; DeLisle, D. M.; Worland, S. T. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc. Natl. Acad. Sci. USA 1999, 96, 11000-7.
135. Dragovich, P. S.; Prins, T. J.; Zhou, R.; Webber, S. E.; Marakovits, J. T.; Fuhrman, S. A.; Patick, A. K.; Matthews, D. A.; Lee, C. A.; Ford, C. E.; Burke, B. J.; Rejto, P. A.; Hendrickson, T. F.; Tuntland, T.; Brown, E. L.; Meador, J. W., 3rd; Ferre, R. A.; Harr, J. E.; Kosa, M. B.; Worland, S. T. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. J. Med. Chem. 1999, 42, 1213-24.
136. Thompson, S. A.; Andrews, P. R.; Hanzlik, R. P. Carboxylmodified amino acids and peptides as protease inhibitors. J. Med. Chem. 1986, 29, 104-11.
137. Engel, J. C.; Doyle, P. S.; Hsieh, I; McKerrow, J. H. Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J. Exp. Med. 1998, 188, 725-34.
138. Dragovich, P. S.; Prins, T. J.; Zhou, R.; Johnson, T. O.; Hua, Y.; Lou, H. T.; Sakata, S. K.; Brown, E. L.; Maldonado, F. C.; Tuntland, T.; Lee, C. A.; Fuhrman, S. A.; Zalman, L. S.; Patick, A. K.; Matthews, D. A.; Wu, E. Y.; Guo, M.; Borer, B. C.; Nayyar, N. K.; Moran, T.; Chen, L.; Rejto, P. A.; Rose, P. W.; Guzman, M. C.; Dovalsantos, E. Z.; Lee, S.; McGee, K.; Mohajeri, M.; Liese, A.; Tao, J.; Kosa, M. B.; Liu, B.; Batugo, M. R.; Gleeson, J. P.; Wu, Z. P.; Liu, J.; Meador, J. W., 3rd; Ferre, R. A. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics. J. Med. Chem. 2003, 46, 4572-85.
139. Dragovich, P. S.; Prins, T. J.; Zhou, R.; Brown, E. L.; Maldonado, F. C.; Fuhrman, S. A.; Zalman, L. S.; Tuntland, T.; Lee, C. A.; Patick, A. K.; Matthews, D. A.; Hendrickson, T. F.; Kosa, M. B.; Liu, B.; Batugo, M. R.; Gleeson, J. P.; Sakata, S. K.; Chen, L.; Guzman, M. C.; Meador, J. W. 3rd.; Ferre, R. A.; Worland, S. T. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics. J. Med. Chem. 2002, 45, 1607-23.
140. Webber, S. E.; Marakovits, J. T.; Dragovich, P. S.; Prins, T. J.; Zhou, R.; Fuhrman, S. A.; Patick, A. K.; Matthews, D. A.; Lee, C. A.; Srinivasan, B.; Moran, T.; Ford, C. E.; Brothers, M. A.; Harr, J. E.; Meador, J. W. 3rd.; Ferre, R. A.; Worland, S. T. Design and synthesis of irreversible depsipeptidyl human rhinovirus 3C protease inhibitors. Bioorg. Med. Chem. Lett. 2001, 11, 2683-6.
141. Dragovich, P. S.; Webber, S. E.; Prins, T. J.; Zhou, R.; Marakovits, J. T.; Tikhe, J. G.; Fuhrman, S. A.; Patick, A. K.; Matthews, D. A.; Ford, C. E.; Brown, E. L.; Binford, S. L.; Meador, J. W. 3rd.; Ferre, R. A.; Worland, S. T. Structure-based design of irreversible, tripeptidyl human rhinovirus 3C protease inhibitors containing N-methyl amino acids. Bioorg. Med. Chem. Lett. 1999, 9, 2189-94.
142. Dragovich, P. S.; Prins, T. J.; Zhou, R.; Fuhrman, S. A.; Patick, A. K.; Matthews, D. A.; Ford, C. E.; Meador, J. W. 3rd.; Ferre, R. A.; Worland, S. T. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics. J. Med Chem. 1999, 42, 1203-12.
143. Dragovich, P. S.; Webber, S. E.; Babine, R. E.; Fuhrman, S. A.; Patick, A. K.; Matthews, D. A.; Reich, S. H.; Marakovits, J. T.; Prins, T. J.; Zhou, R.; Tikhe, J.; Littlefield, E. S.; Bleckman, T. M.; Wallace, M. B.; Little, T. L.; Ford, C. E.; Meador, J. W. 3rd .; Ferre, R. A.; Brown, E. L.; Binford, S. L.; DeLisle, D. M.; Worland, S. T. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies. J. Med. Chem. 1998, 41, 2819-34.
144. Dragovich, P. S.; Webber, S. E.; Babine, R. E.; Fuhrman, S. A.; Patick, A. K.; Matthews, D. A.; Lee, C. A.; Reich, S. H.; Prins, T. J.; Marakovits, J. T.; Littlefield, E. S.; Zhou, R.; Tikhe, J.; Ford, C. E.; Wallace, M. B.; Meador, J. W. 3rd.; Ferre, R. A.; Brown, E. L.; Binford, S. L.; Harr, J. E.; DeLisle, D. M.; Worland, S. T. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies. J. Med. Chem. 1998, 41, 2806-18.
145. Dragovich, P. S.; Zhou, R.; Skalitzky, D. J.; Fuhrman, S. A.; Patick, A. K.; Ford, C. E.; Meador, J. W. 3rd.; Worland, S. T. Solidphase synthesis of irreversible human rhinovirus 3C protease inhibitors. Part 1: Optimization of tripeptides incorporating N-terminal amides. Bioorg. Med. Chem. 1999, 7, 589-98.
146. Roush, W. R.; Gwaltney, S. L.; Cheng, J. M.; Scheidt, K. A.; McKerrow, J. H.; Hansell, E. Vinyl sulfonate esters and vinyl sulfonamides: Potent, irreversible inhibitors of cysteine proteases. J. Am. Chem. Soc. 1998, 120, 10994-10995.
147. Roush, W. R.; Cheng, J.; Knapp-Reed, B.; Alvarez-Hemandez, A.; McKerrow, J. H.; Hansell, E.; Engel, J. C. Potent second generation vinyl sulfonamide inhibitors of the trypanosomal cysteine protease cruzain. Bioorg. Med. Chem. Lett. 2001, 11, 2759-62.
148. Brinen, L. S.; Hansell, E.; Cheng, J.; Roush, W. R.; McKerrow, J. H.; Fletterick, R. J. A target within the target: probing crizain's Pl' site to define structural determinants for the Chagas' disease protease. Structure Fold. Des. 2000, 8, 831-40.
149. Reddick, J. J.; Cheng, J.; Roush, W. R. Relative rates of Michael reactions of 2′-(phenethyl)thiol with vinyl sulfones, vinyl sulfonate esters, and vinyl sulfonamides relevant to vinyl sulfonyl cysteine protease inhibitors. Org. Lett. 2003, 5, 1967-70.
150. Govardhan, C. P.; Abeles, R. H. Inactivation of cysteine proteases. Arch. Biochem. Biophys. 1996, 330, 110-4.
151. Liu, S.; Hanzlik, R. P. Structure-activity relationships for inhibition of papain by peptide Michael acceptors. J. Med. Chem 1992, 35, 1067-75.
152. Reich, S. H.; Johnson, T.; Wallace, M. B.; Kephart, S. E.; Fuhrman, S. A.; Worland, S. T.; Matthews, D. A.; Hendrickson, T. F.; Chan, F.; Meador, J. 3rd.; Ferre, R. A.; Brown, E. L.; DeLisle, D. M.; Patick, A. K.; Binford, S. L.; Ford, C. E. Substituted benzamide inhibitors of human rhinovirus 3C protease: structurebased design, synthesis, and biological evaluation. J. Med. Chem. 2000, 43, 1670-83.
153. Kong, J. S.; Venkatraman, S.; Furness, K; Nimkar, S.; Shepherd, T. A.; Wang, Q. M.; Aube, J.; Hanzlik, R. P. Synthesis and evaluation of peptidyl Michael acceptors that inactivate human rhinovirus 3C protease and inhibit virus replication. J. Med. Chem. 1998, 41, 2579-87.
154. Steindl, T.; Laggner, C.; Langer, T. Human rhinovirus 3C protease: generation of pharmacophore models for peptidic and nonpeptidic inhibitors and their application in virtual screening. J. Chem. Inf. Model. 2005, 45, 716-24.
155. Lall, M. S.; Jain, R. P.; Vederas, J. C. Inhibitors of 3C cysteine proteinases from Picornaviridae. Curr. Top, Med Chem. 2004, 4, 1239-53.
156. Johnson, T. O.; Hua, Y.; Luu, H. T.; Brown, E. L.; Chan, F.; Chu, S. S.; Dragovich, P. S.; Eastman, B. W.; Ferre, R. A.; Fuhrman, S. A.; Hendrickson, T. F.; Maldonado, F. C.; Matthews, D. A.; Meador, J. W. 3rd.; Patick, A. K.; Reich, S. H.; Skalitzky, D. J.; Worland, S. T.; Yang, M.; Zalman, L. S. Structure-based design of a parallel synthetic array directed toward the discovery of irreversible inhibitors of human rhinovirus 3C protease. J. Med. Chem. 2002, 45, 2016-23.
157. Yang, H.; Xie, W.; Xue, X.; Yang, K.; Ma, J.; Liang, W.; Zhao, Q.; Zhou, Z.; Pei, D.; Ziebuhr, J.; Hilgenfeld, R.; Yuen, K. Y.; Wong, L.; Gao, G.; Chen, S.; Chen, Z.; Ma, D.; Bartlam, M.; Rao, Z. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol. 2005, 3, e324.
158. Anand, K.; Ziebuhr, J.; Wadhwani, P.; Mesters, J. R.; Hilgenfeld, R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 2003, 300, 1763-7.
159. Anand, K.; Palm, G. J.; Mesters, J. R.; Siddell, S. G.; Ziebuhr, J.; Hilgenfeld, R. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain. EMBO J. 2002, 21, 3213-24.
160. Hegyi, A.; Ziebuhr, J. Conservation of substrate specificities among coronavirus main proteases. J. Gen. Virol. 2002, 83, 595-9.
161. Ziebuhr, J.; Heusipp, G.; Siddell, S. G. Biosynthesis, purification, and characterization of the human coronavirus 229E 3C-like proteinase. J. Virol. 1997, 71, 3992-3997.
162. Cheah, K. C.; Leong, L. E.; Porter, A. G. Site-directed mutagenesis suggests close functional relationship between a human rhinovirus 3C cysteine protease and cellular trypsin-like serine proteases. J. Biol. Chem. 1990, 265, 7180-7.
163. Huang, C.; Wei, P.; Fan, K.; Liu, Y.; Lai, L. 3C-like proteinase from SARS coronavirus catalyzes substrate hydrolysis by a general base mechanism. Biochemistry 2004, 43, 4568-74.
164. Sousa, M. C.; Kessler, B. M.; Overkleeft, H. S.; McKay, D. B. Crystal structure of HslUV complexed with a vinyl sulfone inhibitor: corroboration of a proposed mechanism of allosteric activation of HsIV by HslU. J. Mol. Biol. 2002, 318, 779-85.
165. Bogyo, M.; McMaster, J. S.; Gaczynska, M.; Tortorella, D.; Goldberg, A. L.; Ploegh, H. Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors. Proc. Natl. Acad. Sci. U S A 1997, 94, 6629-34.
166. Ekici, O. D.; Gotz, M. G.; James, K. E.; Li, Z. Z.; Rukamp, B. J.; Asgian, J. L.; Caffrey, C. R.; Hansell, E.; Dvorak, J.; McKerrow, J. H.; Potempa, J.; Travis, J.; Mikolajczyk, J.; Salvesen, G. S.; Powers, J. C. Aza-peptide Michael acceptors: a new class of inhibitors specific for caspases and other clan CD cysteine proteases. J. Med. Chem. 2004, 47, 1889-92.
167. Kaeppler, U.; Schirmeister, T. New non-peptidic inhibitors of papain derived from etacrynic acid. Med. Chem. 2005, 1, 361-370.
168. Kaeppler, U.; Stiefl, N.; Schiller, M.; Vicik, R.; Breuning, A.; Schmitz, W.; Rupprecht, D.; Schmuck, C.; Baumann, K.; Ziebuhr, J.; T., S. A new lead for non-peptidic active-site directed inhibitors of the SARS coronavirus main protease discovered by a combination of screening and docking methods. J. Med. Chem. 2005, 48, 6832-6842.
169. Koechel, D. A. Ethacrynic acid and related diuretics: relationship of structure to beneficial and detrimental actions. Annu. Rev. Pharmacol. Toxicol. 1981, 21, 265-93.
170. Puschett, J. B. Pharmacological classification and renal actions of diuretics. Cardiology 1994, 84 (Suppl 2), 4-13.
171. Puschett, J. B. Sites and mechanisms of action of diuretics in the kidney. J. Clin. Pharmacol. 1981, 21, 564-74.
172. Ploemen, J. H.; Van Schanke, A.; Van Ommen, B.; Van Bladeren, P. J. Reversible conjugation of ethacrynic acid with glutathione and human glutathione S-transferase P1-1. Cancer Res. 1994, 54, 915-9.
173. Oakley, A. J.; Rossjohn, J.; Lo Bello, M.; Caccuri, A. M.; Federici, G.; Parker, M. W. The three-dimensional structure of the human Pi class glutathione transferase P1-1 in complex with the inhibitor ethacrynic acid and its glutathione conjugate. Biochemistry 1997, 36, 576-85.
174. Cameron, A. D.; Sinning, I.; L'Hermite, G.; Olin, B.; Board, P. G.; Mannervik, B.; Jones, T. A. Structural analysis of human alpha-class glutathione transferase A1-1 in the apo-form and in complexes with ethacrynic acid and its glutathione conjugate. Structure 1995, 3, 717-27.
175. Iersel, M. L.; Ploemen, J. P.; Struik, I.; van Amersfoort, C.; Keyzer, A. E.; Schefferlie, J. G.; van Bladeren, P. J. Inhibition of glutathione S-transferase activity in human melanoma cells by alpha, beta-unsaturated carbonyl derivatives. Effects of acrolein, cinnamaldehyde, citral, crotonaldehyde, curcumin, ethacrynic acid, and trans-2-hexenal. Chem. Biol. Interact. 1996, 102, 117-32.
176. Lo Bello, M.; Oakley, A. J.; Battistoni, A.; Mazzetti, A. P.; Nuccetelli, M.; Mazzarese, G.; Rossjohn, J.; Parker, M. W.; Ricci, G. Multifunctional role of Tyr 108 in the catalytic mechanism of human glutathione transferase P1-1. Crystallographic and kinetic studies on the Y108F mutant enzyme. Biochemistry 1997, 36, 6207-17.
177. Oakley, A. J.; Lo Bello, M.; Mazzetti, A. P.; Federici, G.; Parker, M. W. The glutathione conjugate of ethacrynic acid can bind to human pi class glutathione transferase P1-1 in two different modes. FEBS Lett. 1997, 419, 32-6.
178. Ploemen, J. H.; Bogaards, J. J.; Veldink, G. A.; van Ommen, B.; Jansen, D. H.; van Bladeren, P. J. Isoenzyme selective irreversible inhibition of rat and human glutathione S-transferases by ethacrynic acid and two brominated derivatives. Biochem. Pharmacol. 1993, 45, 633-9.
179. Ploemen, J. H.; van Ommen, B.; Bogaards, J. J.; van Bladeren, P. J. Ethacrynic acid and its glutathione conjugate as inhibitors of glutathione S-transferases. Xenobiotica 1993, 23, 913-23.
180. Ploemen, J. H.; van Ommen, B.; van Bladeren, P. J. Inhibition of rat and human glutathione S-transferase isoenzymes by ethacrynic acid and its glutathione conjugate. Biochem. Pharmacol. 1990, 40, 1631-5.
181. van Iersel, M. L.; Ploemen, J. P.; Lo Bello, M.; Federici, G.; van Bladeren, P. J. Interactions of alpha, beta-unsaturated aldehydes and ketones with human glutathione S-transferase P1-1. Chem. Biol. Interact. 1997, 108, 67-78.
182. Hoffman, D. W.; Wiebkin, P.; Rybak, L. P. Inhibition of glutathione-related enzymes and cytotoxicity of ethacrynic acid and cyclosporine. Biochem. Pharmacol. 1995, 49, 411-5.
183. Jayaram, H. N.; Cooney, D. A.; Milman, H. A.; Homan, E. R.; King, W. M.; Cragoe, E. J. Ethacrynic acid - an inhibitor of L-asparagine synthetase. Biochem. Pharmacol. 1975, 24, 1787-92.
184. Mehanna, A. S.; Dowling, M. Liquid chromatographic determination of hippuric acid for the evaluation of ethacrynic acid as angiotensin converting enzyme inhibitor. J. Pharm. Biomed. Anal. 1999, 19, 967-73.
185. Koechel, D. A.; Cafruny, E. J. Synthesis and structure-activity relationship of some thiol adducts of ethacrynic acid. J. Med. Chem. 1973, 16, 1147-52.
186. Kaeppler, U.; Schirmeister, T. unpublished results.
187. Zhu, S.; Hudson, T. H.; Kyle, D. E.; Lin, A. J. Synthesis and in vitro studies of novel pyrimidinyl peptidomimetics as potential antimalarial therapeutic agents. J. Med. Chem. 2002, 45, 3491-6.
188. Todd, M. J.; Gomez, J. Enzyme kinetics determined using calorimetry: a general assay for enzyme activity? Anal. Biochem. 2001, 296, 179-87.
189. Cross, J. B.; Vreven, T.; Meroueh, S. O.; Mobashery, S.; Schlegel, H. B. Computational investigation of irreversible inactivation of the zinc-dependent protease carboxypeptidase A. J. Phys. Chem. B 2005, 109, 4761-4769.
190. Larsson, P. E.; Marti, S.; Moliner, V.; Andres, J. Catalytic mechanism of HIV protease: A QM/MM study of the nucleophilic and general acid-general base mechanisms. Abst. Pap. ACS 2004, 228, U291-U291.
191. Hensen, C.; Hermann, J. C.; Nam, K. H.; Ma, S. H.; Gao, J. L.; Holtje, H. D. A combined QM/MM approach to protein-ligand interactions: Polarization effects of the HIV-1 protease on selected high affinity inhibitors. J. Med. Chem. 2004, 47, 6673-6680.
192. Topf, M.; Richards, W. G. Theoretical studies on the deacylation step of serine protease catalysis in the gas phase, in solution, and in elastase. J. Am. Chem. Soc. 2004, 126, 14631-14641.
193. Piana, S.; Bucher, D.; Carloni, P.; Rothlisberger, U. Reaction mechanism of HIV-1 protease by hybrid carparrinello/classical MD simulations. J. Phys. Chem. B 2004, 108, 11139-11149.
194. Nemukhin, A. V.; Grigorenko, B. L.; Rogov, A. V.; Topol, I. A.; Burt, S. K. Modeling of serine protease prototype reactions with the flexible effective fragment potential quantum mechanical/molecular mechanical method. Theor. Chem. Acc. 2004, 111, 36-48.
195. Ishida, T.; Kato, S. Theoretical perspectives on the reaction mechanism of serine proteases: The reaction free energy profiles of the acylation process. J. Am. Chem. Soc. 2003, 125, 12035-12048.
196. Beierlein, F.; Lanig, H.; Schurer, G.; Horn, A. H. C.; Clark, T. Quantum mechanical/molecular mechanical (QM/MM) docking: an evaluation for known test systems. Molecular Physics 2003, 101, 2469-2480.
197. Hillier, I. H.; Burton, N. A.; Tai, Z. B.; Gleeson, M. P.; MacKenzie, G.; Sheppard, D. Hybrid QM/MM studies of serine protease catalysis and inhibition. Abst. Pap. ACS 2001, 222, U387-U387.
198. Byun, K.; Gao, J. L. A combined QM/MM study of the nucleophilic addition reaction of methanethiolate and N-methylacetamide. J. Mol. Graphics Modell. 2000, 18, 50-55.
199. Reuter, N.; Dejaegere, A.; Maigret, B.; Karplus, M. Frontier bonds in QM/ MM methods: A comparison of different approaches. J. Phys. Chem. A 2000, 104, 1720-1735.
200. Koritsanszky, T. S.; Coppens, P. Chemical applications of X-ray charge-density analysis. Chem. Rev. 2001, 101, 1583-1627.
201. Wang, G.; Yao, S. Q. Combinatorial synthesis of a small-molecule library based on the vinyl sulfone scaffold. Org. Lett. 2003, 5, 4437-40.
202. Wang, G.; Mahesh, U.; Chen, G. Y.; Yao, S. Q. Solid-phase synthesis of peptide vinyl sulfones as potential inhibitors an activity-based probes of cysteine proteases. Org. Lett. 2003, 5, 737-40.
203. Shenai, B. R.; Lee, B. J.; Alvarez-Hernandez, A.; Chong, P. Y.; Emal, C. D.; Neitz, R. J.; Roush, W. R.; Rosenthal, P. J. Structure-activity relationships for inhibition of cysteine protease activity and development of Plasmodium falciparum by peptidyl vinyl sulfones. Antimicrob. Agents. Chemother. 2003, 47, 154-60.
204. Scheidt, K. A.; Roush, W. R.; McKerrow, J. H.; Selzer, P. M.; Hansell, E.; Rosenthal, P. J. Structure-based design, synthesis and evaluation of conformationally constrained cysteine protease inhibitors. Bioorg. Med. Chem. 1998, 6, 2477-94.
205. Rosenthal, P. J.; Olson, J. E.; Lee, G. K.; Palmer, J. T.; Klaus, J. L.; Rasnick, D. Antimalarial effects of vinyl sulfone cysteine proteinase inhibitors. Antimicrob. Agents Chemother. 1996, 40, 1600-3.